Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Core Viewpoint - Biodexa Pharmaceuticals has secured an exclusive license for OPB-171775, a novel molecular glue aimed at treating gastrointestinal stromal tumors (GIST), which may also have applications in other indications [1][2]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for rare diseases with unmet medical needs [1][13]. - The company is advancing its pipeline, which includes MTX240 (OPB-171775) and eRapa, targeting conditions such as Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer [2][13]. Product Details - MTX240 utilizes a unique molecular glue mechanism that facilitates targeted protein interactions, distinguishing it from conventional kinase inhibitors [3]. - The compound targets GIST driven by mutations in the KIT receptor tyrosine kinase, addressing the challenge of resistance that often develops with existing tyrosine kinase inhibitors (TKIs) [4][5]. Clinical Rationale - MTX240 has demonstrated dose-dependent anti-tumor efficacy in patient-derived xenograft (PDX) models resistant to imatinib and sunitinib, regardless of KIT mutation status [6][8]. - The mechanism of action involves stabilizing SLFN12 to induce apoptosis in GIST cells through a pathway independent of KIT signaling, potentially benefiting a significant proportion of GIST patients [5][9]. Market Opportunity - GIST affects approximately 3,000-4,000 patients annually in the U.S., with 10-15% of patients experiencing resistance to available TKIs, highlighting a substantial unmet medical need [9]. - The global GIST market is valued at around USD 1.3 billion and is projected to grow at an annual rate of 6-10% through 2032, driven by increasing incidence and new therapeutic options [10]. Licensing Agreement - Biodexa has exclusive global rights to develop and commercialize MTX240, except in Japan where Otsuka retains rights. The agreement includes an upfront fee, development milestones, and tiered royalties on net sales [11]. Intellectual Property - MTX240 is protected by composition of matter patents in the U.S., Europe, Japan, and other countries, extending through 2037 without any patent term extension [12].